"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis" by @EugeneSemenovMD
Immune checkpoint inhibitors have improved survival across multiple cancers. However, they can cause cutaneous immune-related adverse events (irAEs). >40 cutaneous eruptions have been associated with ICIs, including immunobullous, lichenoid dermatitis, & psoriasiform. #SID2021
They performed an observational study comparing patients on ICIs to matched controls. They found the overall incidence of immune-related adverse events to be 25% in the real world, lower than estimates in clinical trials. #SID2021
Only 10 cutaneous eruptions were observed with increased incidence in the ICI population. Among them were drug eruptions, bullous pemphigoid, maculopapular eruption, vitiligo, Grover's disease, mucositis, lichen planus, erythroderma, pruritus. #SID2021
Significant delay in presentation of cirAEs in the real world setting! Clinical trials: 5 weeks. Real world setting: 16.5 weeks. Keep that in mind when you see a delayed cutaneous reaction to immune checkpoint inhibitors. #SID2021
Independent risk factors for the development of cutaneous immune-related adverse events included melanoma, RCC, and combination immunotherapy. Older age and anti-CTLA4 monotherapy were independently protective against cutaneous immune-related adverse events. #SID2021
• • •
Missing some Tweet in this thread? You can try to
force a refresh
